Atlas Trials

Fovinaciclib Plus Aromatase Inhibitors and Dual HER2 Blockade in a Response-Adapted Neoadjuvant Strategy for HR-Positive/HER2-Positive Early Breast Cancer

Clinical trial NCT07616427 · RECRUITING

Trial details

NCT number
NCT07616427
Sponsor
Second Affiliated Hospital, Zhejiang University, School of Medicine
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
HR+/HER2+ Early Breast Cancer
Start date
2026-05-20
Primary completion
2028-05-20
Enrollment
100

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.